当前位置: X-MOL 学术BMJ › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Covid-19: Gilead withdraws orphan drug designation from potential treatment after criticism
The BMJ ( IF 93.6 ) Pub Date : 2020-03-26 , DOI: 10.1136/bmj.m1259
Elisabeth Mahase

The US Food and Drug Administration (FDA) has withdrawn orphan drug designation from a potential covid-19 treatment, after criticism that treating covid-19 as a rare disease was “disingenuous.” Pharmaceutical company Gilead requested that the FDA withdraw the designation—which was set to give the company a longer exclusivity period (seven years instead of five) and significant tax incentives—just days after it was given.1 Remdesivir, which works to inhibit viral replication, is a drug currently being investigated as a potential treatment for covid-19 through several …

中文翻译:

Covid-19:批评后,吉利德(Gilead)从潜在治疗中撤回了孤儿药的称号

在批评将covid-19视为罕见疾病后,美国食品和药物管理局(FDA)已从潜在的covid-19治疗中撤回了孤儿药的称号。制药公司吉利德(Gilead)要求FDA在指定后几天就撤回该名称,这是为了给予该公司更长的独占期(从7年而不是5年)和重大税收优惠。1Remdesivir用于抑制病毒复制。 ,是目前正在通过几种药物研究作为covid-19的潜在治疗药物。
更新日期:2020-03-27
down
wechat
bug